retatrutide when will it be available UK Guide: Key Facts on the New Weight-Loss Drug Retatrutide Side Effects Guide: 21

Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer

But medication alone is never the full answer

At-home Noom Biomarkers test kit 17 advanced lab markers that track your metabolic, cardiovascular, and hormonal health in addition to measuring inflammation and key nutrients over time

That dual action is what has made it one of the most talked-about medications in metabolic health

Retatrutide is an investigational medicine that isnt licensed by the MHRA in the UK as of May 2026

This represents the highest weight loss ever recorded in a Phase 3 obesity trial, surpassing even the company's own dual agonist tirzepatide (Mounjaro/Zepbound), which achieved 22.5% in its pivotal studies